Phase 1 Open-Label Dose-Escalation Study of Olaratumlab

Project: Research project

Description

A Phase 1, Open-Label, Dose-Escalation Study of Olaratumab as a Single Agent and in Combination with Doxorubicin, Vincristine/Irinotecan, or High-Dose Ifosfamide in Pediatric Patients with Relapsed or Refractory Solid Tumors (I5B-MC-JGDN)
StatusActive
Effective start/end date12/22/1512/22/20

Funding

  • Eli Lilly and Company

Fingerprint

irinotecan
Ifosfamide
Vincristine
Doxorubicin
Pediatrics
Neoplasms
olaratumab